Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

SONN

Sonnet BioTherapeutics (SONN)

Sonnet BioTherapeutics Holdings Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SONN
DateTimeSourceHeadlineSymbolCompany
11/12/20248:15AMGlobeNewswire Inc.Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” SegmentNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
11/08/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
11/07/20248:22AMEdgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:SONNSonnet BioTherapeutics Holdings Inc
11/06/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
11/06/202412:20PMGlobeNewswire Inc.Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq RulesNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
11/06/20248:22AMEdgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:SONNSonnet BioTherapeutics Holdings Inc
11/06/20247:48AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
11/06/20247:30AMGlobeNewswire Inc.Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug CandidatesNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
11/04/20248:01AMEdgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:SONNSonnet BioTherapeutics Holdings Inc
10/28/20248:01AMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:SONNSonnet BioTherapeutics Holdings Inc
10/17/20247:50AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
10/17/20247:45AMGlobeNewswire Inc.Sonnet BioTherapeutics Inc. Regains Compliance with NasdaqNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
10/09/20247:56AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
10/09/20247:45AMGlobeNewswire Inc.Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in IndiaNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
10/04/20247:30AMGlobeNewswire Inc.Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive ProgramsNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
09/30/20248:00AMGlobeNewswire Inc.Sonnet BioTherapeutics Announces Launch of CEO Corner PlatformNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
09/30/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
09/25/20247:30AMGlobeNewswire Inc.Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock SplitNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
09/18/20247:36AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
09/18/20247:30AMGlobeNewswire Inc.Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid TumorsNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
09/12/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
09/09/20243:08PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
09/04/20248:15AMGlobeNewswire Inc.Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell SeriesNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
08/30/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
08/19/20244:28PMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
08/19/20244:27PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
08/19/20247:50AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
08/19/20247:45AMGlobeNewswire Inc.Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic CancerNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
08/14/20247:45AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SONNSonnet BioTherapeutics Holdings Inc
08/14/20247:41AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:SONN